Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 11/20 | 0.75 |
| ▸ | MEF2D | Q14814 | 7/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.61 |
| ▸ | MMP1 | P03956 | 2/20 | 0.60 |
| ▸ | MMP2 | P08253 | 2/20 | 0.60 |
| ▸ | MMP9 | P14780 | 2/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21232320 | 0.86 | HDAC4 (1.00) | HDAC4MEF2D | |
| SCHEMBL10198766 | 0.85 | HDAC1 (0.59) | HDAC4MEF2DHDAC1HDAC2HDAC3 | |
| SCHEMBL13949978 | 0.82 | HDAC1 (0.72) | HDAC4MEF2DHDAC1HDAC2HDAC3 | |
| N-Benzylaniline SCHEMBL28648928 | 0.81 | HDAC4 (0.70) | HDAC4MEF2DHDAC1HDAC2HDAC3 | |
| SCHEMBL13762663 | 0.81 | HDAC8 (0.77) | HDAC4MEF2DHDAC1HDAC2HDAC3 | |
| SCHEMBL21232325 | 0.80 | HDAC4 (1.00) | HDAC4MEF2D | |
| SCHEMBL21232043 | 0.80 | HDAC4 (1.00) | HDAC4MEF2D | |
| SCHEMBL11461242 | 0.79 | MAPT (0.59) | HDAC4MEF2DHDAC1FFAR1 | |
| SCHEMBL11461243 | 0.79 | MAPT (0.59) | HDAC4MEF2DHDAC1FFAR1 | |
| SCHEMBL25118498 | 0.79 | HDAC1 (0.72) | HDAC4MEF2DHDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-20180117011-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2018-05-03 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20150328320-A1 | Novel Pharmaceutical Composition | GLAXO GROUP LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150306099-A1 | COMBINATION | GLAXOSMITHKLINE LLC | 2015-10-29 | — | — | US | disclosed |
| US-9155706-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2015-10-13 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8580304-B2 | Pharmaceutical composition | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130266649-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120183613-A1 | Novel Pharmaceutical Composition | NOVARTIS PHARMACEUTICALS CORPORATION | 2012-07-19 | — | — | US | disclosed |
| US-20110160130-A1 | CANCER TREATMENT METHOD | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160130-A1 | CANCER TREATMENT METHOD | MPL, TPO, PROKR1 | HDAC4 2725/4885MEF2D 4836/4885HDAC1 3143/4885 |
| US-20150306099-A1 | COMBINATION | VHL, CA5A, HRAS | HDAC4 92/4885MEF2D 4016/4885HDAC1 111/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | HDAC4 1814/4885MEF2D 4568/4885HDAC1 649/4885 |
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | HDAC4 1107/4885MEF2D 2367/4885HDAC1 654/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | HDAC4 3077/4885MEF2D 2767/4885HDAC1 2055/4885 |
| US-20120183613-A1 | Novel Pharmaceutical Composition | PHOSPHO1, PLA2G2C, TTR | HDAC4 1122/4885MEF2D 2474/4885HDAC1 1261/4885 |
| US-20130266649-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | HDAC4 1122/4885MEF2D 2474/4885HDAC1 1261/4885 |
| US-20150328320-A1 | Novel Pharmaceutical Composition | TTR, PLA2G2C, LIPA | HDAC4 1099/4885MEF2D 2102/4885HDAC1 1442/4885 |
| US-20180117011-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | AR, PIK3CA, NR5A1 | HDAC4 67/4885MEF2D 1024/4885HDAC1 7/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC4 121/4885MEF2D 2840/4885HDAC1 67/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | HDAC4 121/4885MEF2D 2840/4885HDAC1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.